In vitro activity of antifungals against Zygomycetes.
To date, no reference standard for therapy for zygomycosis has been established because there are insufficient clinical data with which to make such a judgement. Knowledge of the species responsible for the infection and its antifungal susceptibility profile has become increasingly important in the management of patients. Amphotericin B is the most active drug against all the species involved, followed by posaconazole, whereas voriconazole has no activity. Echinocandins are completely inactive in vitro, but may be an interesting option when used in combination with other drugs.
Alastruey-Izquierdo
A
A
Mycology Reference Laboratory, National Centre for Microbiology, Carlos III Institute of Health (Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III), Madrid, Spain.
Castelli
M V
MV
Cuesta
I
I
Zaragoza
O
O
Monzón
A
A
Mellado
E
E
Rodríguez-Tudela
J L
JL
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D054714:Echinocandins / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009090:Mucorales / Q000187:drug effects* / Q000302:isolation & purification; D009091:Mucormycosis / Q000382:microbiology*; D011743:Pyrimidines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B; D065819:Voriconazole